Commonness of Factor V Leiden, Prothrombin G20210A and Methylenetetrahydrofolate Reductase C677T Mutations among Patients with Thromboembolism in the Western Black Sea (Zonguldak) Region of Turkey

Muammer Bilici1*, Basak Delikanli Corakci1, Yasin Ozturk1 and Sehmus Ertop2

1Department of Internal Medicine, Bülent Ecevit University, School of Medicine, Turkey
2Department of Hematology, Bülent Ecevit University, School of Medicine, 67600 Zonguldak, Turkey

Abstract

Introduction: Venous thromboembolism (VTE) remains a life-threatening disease. Screening for inherited risk factors in selected patients may have an impact on treatment approaches to VTE. In this study, we aimed to assess the frequency of factor V Leiden (FVL), prothrombin G20210A and MTHFR C677T gene mutations among idiopathic VTE patients and healthy population in Zonguldak province and the Western Black Sea Region of Turkey.

Methods: The present study included 157 patients with VTE and 135 healthy individuals. FVL, prothrombin G20210A and MTHFR C677T gene mutations were investigated in patients hospitalized for VTE and healthy subjects.

Results: In agreement with the previously reported publications in Turkey and Europe, the prevalence of FVL, prothrombin G20210A and MTHFR C677T gene mutations were 6.7%, 2.9% and 43.7%, respectively, among healthy population. In VTE patients, it was observed that the rates of FVL, prothrombin G20210A increased significantly as well as the frequency of homozygosity for MTHFR in VTE patients was higher than controls.

Conclusion: Screening for genetic disorders such as FVL, prothrombin G20210A and MTHFR C677T gene mutations should be evaluated in patients presented with unexplained VTE.

Keywords: Venous thromboembolism; Factor V Leiden; Prothrombin G20210A; MTHFR C677T

Introduction

Although the exact incidence of venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is unknown. In general population, it has been estimated to be 1-2 per 1000 annually and increases with age [1-4]. And also it remains a serious health problem with an unacceptable mortality rate that the 30-day mortality was reported to be 6.4% for all patients with VTE [5]. Overall, idiopathic (unprovoked) VTE comprises 25% to 50% of all cases with first-time VTE. A significant number of people who have a first episode of VTE will have a recurrent event, particularly in the days or weeks following the first episode, then the risk of recurrence declines in time [2,3,6]. The provoked VTE by acquired risk factors has lower risk of recurrence than unprovoked VTE whose recurrence risk for VTE is approximately 5-7% per year [7]. Cushman et al. reported that the first-year incidences of recurrent VTE among patients with VTE and idiopathic VTE were 7.7% and 7.8%, respectively [8]. Previous studies have revealed that the annual risk of recurrence due to thrombophilia is not found to be significantly higher than the others without any thrombophilic defects, among patients with an initial idiopathic VTE [9-11].

Thrombosis does not occur in most people with thrombophilia. The acquired risk factors such as advanced age (>75 years), immobilization, inflammation, trauma, surgery, pregnancy, oral contraception use, obesity (body mass index [BMI] >30 kg/m2), diabetes, hormonal replacement therapy, cancer, lupus anticoagulant, sickle cell anemia and other hemolytic anemias are the important provoking factors for VTE [12,13]. In cases of unprovoked VTE, VTE at young age (<45 years), recurrent VTE, VTE in unusual sites, VTE in the setting of a strong family history of VTE and recurrent pregnancy loss, laboratory testing for hypercoagulable states should be considered to uncover any inherited abnormalities [14]. Although, testing for inherited hypercoagulable states (including antithrombin deficiency, protein C and S deficiency, hyperhomocysteinemia, FVL, prothrombin G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T gene mutations) can uncover an abnormality in more than 60% of patients presenting with a first VTE, it minimally influences VTE management in most of these patients. Thus, laboratory testing for hypercoagulable states is recommended if the results of individual tests will affect the choice of anticoagulant agent, duration and intensity of anticoagulation therapy, therapeutic monitoring, family screening, family planning and choice of concomitant medications [3,7,12,14]. It is obvious that thromboprophylaxis is perceived as being important to patients in at moderate or high risk for VTE [15].

In this study, we aimed to evaluate demographic and clinical features of our patients with idiopathic VTE and assess the frequency of factor V Leiden (FVL), prothrombin G20210A and MTHFR C677T gene mutations among idiopathic VTE patients and healthy population as a screening test.

*Corresponding author: Bilici M, Department of Internal Medicine, Bülent Ecevit University, School of Medicine, Zonguldak, Turkey, Zip Code: 67600, Tel: +905387220925, E-mail: drmbilici@hotmail.com

Received June 18, 2018; Accepted June 25, 2018; Published June 30, 2018


Copyright: © 2018 Bilici M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Materials and Methods

Study population

Screening for Factor V Leiden, prothrombin G20210A and MTHFR C677T gene mutations was performed in patients hospitalized for venous thromboembolism (DVT, PE, Cerebral and Abdominal vein thrombosis) and healthy subjects, from October 2010 to May 2017. The patients from neighboring provinces in this region are admitted to our hospital as well. The study population consisted of the 157 consecutive patients with idiopathic VTE and 135 healthy subjects. The patients who have acquired risk factors for VTE such as advanced age (>75 years), malignancy, trauma, immobilization and obesity (BMI>30 kg/m2) were excluded from the study. The diagnosis of venous thromboembolism was confirmed by Doppler ultrasonography or computed tomography (CT) angiography [16]. The study protocol, conforms to the ethical guidelines of the world medical association’s declaration of Helsinki as reflected in a priori approval by the Local Ethics Committee of Bulent Ecevit University, Zonguldak, Turkey. All participants were fully informed about the study protocol and informed consent was obtained from all individuals.

Laboratory tests

From each patient, peripheral venous blood samples were drawn from antecubital vein into tubes containing ethylenediaminetetraacetic acid (EDTA) using standard operational procedure. Hemoglobin (Hgb), Platelet Count (PLT) and Mean Platelet Volume (MPV) were obtained from the automated complete blood count using a Coulter LH 780 Hematology Analyzer (Beckman Coulter Inc. Brea., CA, USA). For detecting Factor V Leiden, prothrombin G20210A and MTHFR C677T gene mutations, following procedures were used: Genomic DNA was extracted from peripheral blood leucocytes (200 μl of total blood) by using a Macherey-Nagel (MN) Nucleospin blood® DNA extraction kit (cat. no. 740.951.250) according to the manufacturer’s instructions. Factor V Leiden, prothrombin G20210A and MTHFR C677T gene mutations were detected by Dr. Zeydanli Type I PCR System (Ankara, Turkey) based TaqMan® 5′ nuclease assay method in ABI 7500 (Applied Biosystems, Foster City, CA, USA). PCR reaction was performed according to the manufacturer’s instructions. The reactions were started at 95°C for 10 min, followed by 32 cycles of 95°C for 15 s and 60°C for 1 min.

Statistical analyses

Statistical analysis was performed with SPSS (Version 19.0 for Windows, Chicago, Illinois). Descriptive statistics of continuous variables are given as mean, standard deviation, median, minimum, and maximum values. Categorical variables are presented as frequency and percentage. The Shapiro-Wilk test was used as a test of normality. The Mann Whitney U test was used for non-parametric two-group comparisons. Pearson chi-square, Yates chi-square and Fisher exact chi-square tests were used for group comparisons of categorical variables. For all statistical comparisons a p value of below 0.05 was assumed to be statistically significant.

Results

Demographic characteristics of patients and controls are shown in Table 1. In terms of age and gender, there were no significant differences between the patients with VTE and controls (p>0.05). The distributions of Factor V Leiden, prothrombin, G20210A and MTHFR C677T gene mutations among all participants were given in Figure 1. Factor V Leiden and prothrombin G20210A mutations were found to be significantly higher in patients than controls (p<0.05), whereas there was no significant difference between the groups regarding MTHFR C677T gene mutation (p=0.619). One hundred eighteen of the 157 patients with VTE (75.2%) and 66 of the 135 healthy subjects

<table>
<thead>
<tr>
<th>VTE patients n=157</th>
<th>Controls n=135</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (year)</strong></td>
<td>41.25±12.86</td>
<td>38.56 ± 7.30</td>
</tr>
<tr>
<td><strong>Gender % (Male/Female)</strong></td>
<td>84 (53.5)/73 (46.5)</td>
<td>62 (46)/73 (54)</td>
</tr>
<tr>
<td><strong>Hgb (g/dL)</strong></td>
<td>13.50 ± 1.52</td>
<td>13.30 ± 0.95</td>
</tr>
<tr>
<td><strong>Plt (×1000/mm³)</strong></td>
<td>280.95 ± 81.61</td>
<td>251.58 ± 58.29</td>
</tr>
<tr>
<td><strong>FVL (%)</strong></td>
<td>69 (43.9)</td>
<td>9 (6.7)</td>
</tr>
<tr>
<td><strong>Prothrombin G20210A (%)</strong></td>
<td>19 (12.1)</td>
<td>4 (2.9)</td>
</tr>
<tr>
<td><strong>MTHFR C677T (%)</strong></td>
<td>66 (42)</td>
<td>59 (43.7)</td>
</tr>
</tbody>
</table>

**Abbreviations:** VTE: Venous Thromboembolism; Plt: Platelet Count; MPV: Mean Platelet Volume; FVL: Factor V Leiden; MTHFR: Methylen Tetrahydrofolate Reductase; sd: Standard Deviation.

Table 1: Characteristics of 137 consecutive patients with VTE and 135 controls.

![Figure 1: Frequency of factor V Leiden, Prothrombin G20221A and MTHFR C677T among VTE patients and controls.](image-url)
that 597 (31.3%) of the 1907 patients with a first idiopathic VTE were
with a rate of 35.7% and 8.3%, respectively. Roldan et al. reported
(43.9%) with VTE and 56 were heterozygous and 13 were homozygous
consistent with the previously reported publications in Turkey and
of inherited thrombophilia to show some variation in different regions
Turkey between Europe and Asia as if a bridge allows the distribution
were 4.6%, 8.4%, 9.8%, and 15.2% respectively [21-25]. The location of
regions of Southeastern, Aegean and the cities of Ankara and Tokat
were 4.2% and 15.2%. The lowest frequency of FVL mutation was found to be
in the Thrace region and the results of surveys conducted in the
common US and European populations. FVL is relatively uncommon
in African, Australian and Asian populations [19,20]. In Turkish
data, the prevalence of FVL mutation varies in the range of 4.2% and
15.2%. The lowest frequency of FVL mutation was found to be 2.42% in the
20-25% of patients with a first idiopathic VTE and 40-50% of those with recurrent VTE. Homozygotes (about 0.06 to
0.25% of the population) are much less common than heterozygotes
but homozygous for factor V Leiden is associated with much higher
frequencies of heterozygosity and homozygosity for MTHFR
manner. Thirty-four patients had combined mutations.
Two patients had both FVL and PT mutations, 23 patients had both
FVL and MTHFR mutations, 7 patients had both PT and MTHFR
mutations, and a combination of FVL and PT G20210A and MTHFR
C677T gene mutations was detected in 2 cases (Figure 2). No significant
differences existed between genders.

Discussion

Factor V Leiden (FVL), prothrombin gene mutation and MTHFR
mutations are the most common genetic disorders associated with
VTE [17,18]. The prevalence of FVL varies according to geography
and ethnicity as well as it is approximately 5% in general population.
It can also account for 20-25% of patients with a first idiopathic VTE
and 40-50% of those with recurrent VTE. Homozygotes (about 0.06 to
0.25% of the population) are much less common than heterozygotes
but homozygous for factor V Leiden is associated with much higher
relative risk for VTE. Although, the prevalence varies from 3 to 8% in
common US and European populations. FVL is relatively uncommon
in African, Australian and Asian populations [19,20]. In Turkish
population, the prevalence of FVL mutation varies in the range of 4.1%
and 3.6%. The lowest frequency of FVL mutation was found to be
4.28% in the Thrace region and the results of surveys conducted in the
regions of Southeastern, Aegean and the cities of Ankara and Tokat
were 4.6%, 8.4%, 9.8%, and 15.2% respectively [21-25]. The location of
Turkey between Europe and Asia as if a bridge allows the distribution
of inherited thrombophilia to show some variation in different regions
of Turkey. The prevalence of FVL in our control group (6.7%) was
consistent with the previously reported publications in Turkey and
Europe. Furthermore, in our study, FVL was found in 69 patients
(43.9%) with VTE and 56 were heterozygous and 13 were homozygous
with a rate of 35.7% and 8.3%, respectively. Roldan et al. reported
that 597 (31.3%) of the 1907 patients with a first idiopathic VTE were
tested positive for thrombophilia in their study, as well as 149 (7.8%) of
patients had FVL mutation [26]. In a study of a Croatian population,
Alfirević et al. found that the frequency of FVL mutation was 16% among
VTE patients and all of these were heterozygous mutations
[19]. In Turkish population, the results of the studies conducted on the
frequency of FVL mutation among VTE patients vary. Akar et al. found
that the prevalence of FVL mutation in thrombosis cases was 9.8% [27].
Furthermore, the prevalence of FVL mutation was reported as 37.5%
by Gul et al. [28]. In another study conducted on patients with a history
of DVT, it was found as 24.6% by Kalkanli et al. 22.9% and 1.6% of the
patients bearing FVL mutation were heterozygous and homozygous,
respectively [29]. On the other hand, there are some reports from
Turkey that found the FVL mutation in 20% of patients with VTE [30].
In our study, the frequency of FVL in patients with idiopathic VTE
is higher than the previous reports.

The second most common cause of inherited thrombophilia is PT
gene mutation. It has been reported to increase the risk of VTE almost
threefold [31]. In our study, the frequency of PT gene mutation in
healthy group was 2.9%, while it was higher in the group of patients
with thromboembolic disease (12.1%). All of them were heterozygous.
These results were in accordance with the findings already reported in
other Caucasian populations which is present in 2-4% [32]. PT gene
mutation is more common in European countries that it was reported to
be present in 3-17% of patients with VTE and 1-8% in healthy controls
[33]. There are some reports from our geographic area (Bulgaria,
Greece, Azerbaijan and Romania) that showed the prevalence of PT
gene mutation in the range of 2.77% and 7.0% [22,34,35]. In Turkish
population, Ayvildiz et al. reported that the prevalence of PT gene
mutation was 6.5% in patients with VTE and 1.2% in the healthy group
[36]. Akar et al. found the mutation as 2.7% among healthy group and
6.25% in patients with DVT [37]. In another study, the PT gene
mutation was found to be 27.5% in patients with VTE, by Yilmaz et
al. [38].

Besides the above mentioned genetic factors, MTHFR mutation
is recognized to be one of the most common inherited risk factors
for VTE. However, the role of MTHFR polymorphisms in VTE is
troversial [37,40]. In our study, the frequency of heterozygous
and homozygous MTHFR mutations appeared to be 40.7% and
2.9%, respectively, in healthy subjects. Sazci et al. reported that the
frequencies of heterozygosity and homozygosity for MTHFR (C677T)
in Turkish population were 47.4% and 9.6%, respectively [41]. Our
ratios were lower than this study, this difference may be related to
the population.
the study group size. In our study, we observed that the frequencies of heterozygous and homozygous MTHFR mutations were 30.6% and 11.5%, respectively, in patients with idiopathic VTE. There was no significant difference between the patients and controls in terms of MTHFR mutation whereas, homozygous MTHFR mutation rate was higher in patients with VTE than healthy controls. In patients with VTE, Sahin et al. showed that the frequency of MTHFR mutation was 60% (47.3% heterozygous and 12.7% homozygous) [25]. In another study including 1507 patients with recurrent pregnancy loss conducted by Incebiyik et al. reported that the frequency of heterozygous and homozygous was found to be 40.61% and 8.29%, respectively [42].

One or more inherited risk factor can be detected in almost half of patients who have suffered venous thrombosis [1]. In addition, the coexistence of several inherited risk factors accounting for VTE, increases the risk of recurrent VTE [43]. In our study, FVL, prothrombin and MTHFR mutations were found in 43.9%, 12.1% and 42%, respectively, of the patients, whereas 20.8% of patients had no mutations. Furthermore, two or more mutations were detected in 21.7% of patients with idiopathic VTE. Our findings were consistent with the previous studies in which the high rate of the presence of any of inherited risk factors among patients with venous thrombosis was stated [19,25,42,44].

The results of our study give us some new information on commonness of thrombosis related genetic mutations in Turkish population. Nevertheless, it is not sufficient to generalize our findings to the whole population, due to the small sample size and limited power of the study.

Conclusion

Our findings showed that the prevalence of FVL, MTHFR and PT gene mutations among healthy subjects who are living in the Western Black Sea region of Turkey, were consistent with the previously reported publications in Turkey and Europe. We observed that the patients with idiopathic VTE had significantly more FVL and PT gene mutations than healthy individuals. Thus, these genetic disorders should be evaluated in patients presented with unexplained VTE. We believe that the results of our study will contribute in part to indicate the distribution and prevalence of FVL, MTHFR and PT gene mutations in Turkish population.

Acknowledgments

The authors would like to thank the patients who willingly participated in the study.

References


